ELMMB logo
Facebook logo Twitter logo
Menu
MHRA Drug Safety Updates

MHRA Drug Safety Updates

MHRA Yellow Card Scheme: please help to reverse the decline in reporting of suspected adverse drug reactions 

Drug Safety Update MHRA May 2019 .pdf

Drug Safety Update MHRA May 2019 .pdf
Summary: Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions, Tofacitinib (Xeljanzâ–Ľ): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing. Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy
File Size: 512KB
File Type: application/pdf
Created: 22 May 2019
Last Modified: 20 June 2019